Equity Profile

KRYS

Krystal Biotech, Inc.

Health CareBiotechnology$10.7B

Mar18Mon

Pre-Earnings Brief

UpcomingQ2-2026Pre-Market9:00 AM EDT

Company Snapshot

Krystal Biotech, Inc. is a biotechnology company focused on developing innovative gene therapies for skin diseases....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

N/A

Revenue Growth

Revenue growth will provide insight into the company's market demand and product acceptance.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

KRYS Q2-2026 Earnings Preview

Context

Company Snapshot

Krystal Biotech, Inc. is a biotechnology company focused on developing innovative gene therapies for skin diseases. With a market cap of $11 billion, it operates in the health care sector, addressing significant unmet medical needs in dermatology.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

75%

Avg EPS Surprise

+23.84%

Avg Stock Reaction

-1.56%

Last Quarter Recap

In Q1 2026, Krystal Biotech reported an EPS of $1.83, exceeding estimates by 26.21%. The stock reacted positively, gaining 7.86% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Overall, Wall Street appears cautiously optimistic ahead of the earnings report, given the company's recent performance.

Bull Case

If Krystal Biotech continues to beat EPS estimates, it could signal strong demand for its products and lead to further stock price appreciation.

Bear Case

Conversely, if the company fails to meet expectations or provides weak guidance, it could trigger a significant sell-off, similar to past misses.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the expected EPS for Q2-2026?

The EPS figure will be critical in determining the company's profitability and could influence investor sentiment significantly.

What are the revenue expectations for the upcoming quarter?

Revenue figures will provide insight into the company's growth trajectory and market demand for its products.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for Krystal Biotech to exceed EPS expectations based on its recent performance trends.

Supporting Evidence

The company has a 75% EPS beat rate over the last eight quarters, indicating a strong track record of exceeding expectations.

Options pricing suggests a smaller move than historical averages, indicating potential for a larger surprise.

Key Risk

If the EPS comes in above $2.00, it could significantly challenge the current consensus.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance hinges on whether Krystal Biotech can maintain its growth trajectory and meet or exceed earnings expectations.

Bull Confirmed If

An EPS of $2.00 or higher would confirm the bull case, indicating strong profitability.

Bear Confirmed If

An EPS below $1.50 would confirm the bear case, suggesting potential issues with demand or cost management.

Pre-Earnings Positioning

Options Market

Implied Move

±3.35%

Historical Avg

±7.7%

Pricing cheap

The options market is pricing in a modest move of about 3.35%, suggesting that traders are anticipating a relatively stable reaction to the earnings report.

Options are pricing ±3.3% while KRYS has averaged ±7.7% over the last 8 prints — setup is pricing cheap.

Detail

ATM IV

0.4%

30d HV

38.7%

Calls (1K)P/C Ratio: 0.13Puts (3K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options pricing cheap in Health Care

n=30

Fade rate: 13 of 29 (45%)

This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 5.5%, with a raw directional average of +2.9% (modestly positive historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Krystal Biotech beats expectations, history suggests a potential stock increase of around 2.6%, confirming a positive outlook.

In-Line / Cautious

If results are in line with expectations, the stock may experience a muted reaction, reflecting cautious sentiment.

Miss

A miss could lead to a decline of approximately 14.05%, similar to past performance when expectations were not met.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on product pipeline advancements and their expected timelines.
2Insights into market demand for existing products and any new launches.
3Management's commentary on cost management and operational efficiencies.
4Guidance on future revenue expectations and market conditions.
5Discussion on competitive landscape and how Krystal plans to maintain its market position.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Gen Digital Inc.

Company Snapshot

Krystal Biotech, Inc. is a biotechnology company focused on developing innovative gene therapies for skin diseases....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

N/A

Revenue Growth

Revenue growth will provide insight into the company's market demand and product acceptance.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

KRYS Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

75%

Avg EPS Surprise

+23.84%

Avg Stock Reaction

-1.56%

Last Quarter Recap

In Q1 2026, Krystal Biotech reported an EPS of $1.83, exceeding estimates by 26.21%. The stock reacted positively, gaining 7.86% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Overall, Wall Street appears cautiously optimistic ahead of the earnings report, given the company's recent performance.

Bull Case

If Krystal Biotech continues to beat EPS estimates, it could signal strong demand for its products and lead to further stock price appreciation.

Bear Case

Conversely, if the company fails to meet expectations or provides weak guidance, it could trigger a significant sell-off, similar to past misses.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the expected EPS for Q2-2026?

The EPS figure will be critical in determining the company's profitability and could influence investor sentiment significantly.

What are the revenue expectations for the upcoming quarter?

Revenue figures will provide insight into the company's growth trajectory and market demand for its products.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for Krystal Biotech to exceed EPS expectations based on its recent performance trends.

Supporting Evidence

The company has a 75% EPS beat rate over the last eight quarters, indicating a strong track record of exceeding expectations.

Options pricing suggests a smaller move than historical averages, indicating potential for a larger surprise.

Key Risk

If the EPS comes in above $2.00, it could significantly challenge the current consensus.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance hinges on whether Krystal Biotech can maintain its growth trajectory and meet or exceed earnings expectations.

Bull Confirmed If

An EPS of $2.00 or higher would confirm the bull case, indicating strong profitability.

Bear Confirmed If

An EPS below $1.50 would confirm the bear case, suggesting potential issues with demand or cost management.

Pre-Earnings Positioning

Options Market

Implied Move

±3.35%

Historical Avg

±7.7%

Pricing cheap

The options market is pricing in a modest move of about 3.35%, suggesting that traders are anticipating a relatively stable reaction to the earnings report.

Options are pricing ±3.3% while KRYS has averaged ±7.7% over the last 8 prints — setup is pricing cheap.

Detail

ATM IV

0.4%

30d HV

38.7%

Calls (1K)P/C Ratio: 0.13Puts (3K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options pricing cheap in Health Care

n=30

Fade rate: 13 of 29 (45%)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Krystal Biotech beats expectations, history suggests a potential stock increase of around 2.6%, confirming a positive outlook.

In-Line / Cautious

If results are in line with expectations, the stock may experience a muted reaction, reflecting cautious sentiment.

Miss

A miss could lead to a decline of approximately 14.05%, similar to past performance when expectations were not met.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on product pipeline advancements and their expected timelines.
2Insights into market demand for existing products and any new launches.
3Management's commentary on cost management and operational efficiencies.
4Guidance on future revenue expectations and market conditions.
5Discussion on competitive landscape and how Krystal plans to maintain its market position.